Treatment of Tumors of the Choroid Plexus Epithelium

Stopped early · Phase 3

Conditions studied: Choroid Plexus Tumors

In brief

The goal of this clinical research study is to compare carboplatin to cyclophosphamide when given with etoposide, vincristine, and radiation therapy in the treatment of choroid plexus tumors. The safety of these 2 combination therapies will also be compared. Objectives: OVERALL AIM: To improve choroid plexus tumor treatment through better understanding of the tumor biology and through increased knowledge about the benefit of specific treatment elements. Specific Objectives: The study will have a prephase to evaluate the feasibility of the following randomized study (main phase). Pre-Phase (completed 2005) Primary Specific Objective: To determine the number of patients accountable per year for randomization in a worldwide study. Secondary Specific Objective: To measure the number of drop outs and to describe the toxicity of the chemotherapy. Main Phase (started in 2006) Primary Specific Objective: To compare the survival times after cyclophosphamide based treatment with the survival times after carboplatin based treatment in choroid plexus tumor patients. Main Phase Secondary Specific Objectives: 1. To compare the resectability of choroid plexus tumors after two blocks of cyclophosphamide based treatment with the resectability after two blocks of carboplatin based treatment. 2. To compare response rates of incompletely resected choroid plexus tumors to two blocks of cyclophosphamide based treatment with the response rates after two blocks of carboplatin based treatment. 3. To determine the prognostic relevance of histological atypia and SV40 in choroid plexus tumors.

Key facts

Study ID

NCT00500890

Run by

M.D. Anderson Cancer Center

People needed

2

Starts

2005-09-02

Expected to finish

2017-12-14

Last updated by the study team

2020-02-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The reference center has confirmed the receipt of slides sent (For randomization only = form 2)
• The postoperative imaging has been done and the result is available (for randomization only = for form 2 only)
• Indication criteria: Choroid plexus papilloma (Gr I) with histologically confirmed metastases. (For randomization only = use form 2).
• Indication criteria: Atypical choroid plexus papilloma or anaplastic choroid plexus papilloma histology with either metastases or postoperative residual tumor. (For randomization only = use form 2).
• Indication criteria: Choroid plexus carcinoma, regardless of histologically confirmed metastases or residual tumor. (For randomization only = use form 2).
• Informed consent signed (required for registration = form 1, and for randomization = form 2)
• Patients must have the following: WBC > 2000/ul, platelets >85 000/ul, serum creatinine in normal range, pregnancy test negative, hearing loss less than 30dB at 3000 Hz.

You may not qualify if…

• Previous irradiation or chemotherapy. (Exclusion from randomization only)
• The protocol did not pass the local centre required approvals, such as the Ethics Committee or the scientific review.
• Previous immunotherapy or antiangiogenic therapy (Exclusion from randomization only)

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.